IPP Bureau
FDA approves Pfizer’s ADCETRIS combination regimen for the treatment of Relapsed/Refractory DLBCL
By IPP Bureau - February 13, 2025
Approval is based on positive data from the Phase 3 ECHELON-3 trial
Utthunga partners with VindAir to advance smart solutions for pharma industry
By IPP Bureau - February 13, 2025
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Peter Bains to replace Jonathan Hunt as CEO of Syngene
By IPP Bureau - February 11, 2025
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Lupin receives approval from USFDA for Ipratropium Bromide Nasal Solution
By IPP Bureau - February 11, 2025
Ipratropium Bromide Nasal Solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis
Jagsonpal Pharmaceuticals appoints Sachin Jain as CFO
By IPP Bureau - February 10, 2025
He has over 23 years of experience across sectors
.jpg "Briefs: Caplin Point Laboratories, Hikal and Cipla")
Briefs: Caplin Point Laboratories, Hikal and Cipla
By IPP Bureau - February 10, 2025
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
Zydus Lifesciences posts Q3 FY25 net profit higher at Rs 1,024 Cr
By IPP Bureau - February 10, 2025
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
Wockhardt posts Q3 net profit at Rs. 20 Cr
By IPP Bureau - February 10, 2025
Wockhardt also saw its revenue from operations increased 3% to Rs. 721 crore during Q3 FY25
Cosmo and Glenmark receives UK MHRA approval to market Winlevi in UK
By IPP Bureau - February 10, 2025
NATCO, Lupin receive ANDA approval for Bosentan tablets for oral suspension
By IPP Bureau - February 10, 2025
TFOS is indicated for the treatment of pulmonary arterial hypertension
Aurbindo Pharma posts Q3 FY25 profit at Rs. 846 Cr
By IPP Bureau - February 08, 2025
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
FDA approves EMBLAVEO for the treatment of adults with complicated intra-abdominal infections
By IPP Bureau - February 08, 2025
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
NURA AI Health Screening Centre Bengaluru celebrates 4th anniversary of transforming lives through early detection
By IPP Bureau - February 08, 2025
Plans underway to expand screening capacity by 50% for greater accessibility
Merck reports 2024 sales at $64.2 billion
By IPP Bureau - February 07, 2025
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Akums reports Q3 FY25 adjusted PAT at Rs. 66.3 Cr
By IPP Bureau - February 07, 2025
Branded formulation business continues to perform well across domestic and export markets
